Oxaliplatin(IV) Prodrugs Functionalized with Gemcitabine and Capecitabine Induce Blockage of Colorectal Cancer Cell Growth—An Investigation of the Activation Mechanism and Their Nanoformulation

Carlo Marotta,Damiano Cirri,Ioannis Kanavos,Luisa Ronga,Ryszard Lobinski,Tiziana Funaioli,Chiara Giacomelli,Elisabetta Barresi,Maria Letizia Trincavelli,Tiziano Marzo,Alessandro Pratesi

DOI: https://doi.org/10.3390/pharmaceutics16020278

IF: 6.525

2024-02-16

Pharmaceutics

Abstract:The use of platinum-based anticancer drugs, such as cisplatin, oxaliplatin, and carboplatin, is a common frontline option in cancer management, but they have debilitating side effects and can lead to drug resistance. Combination therapy with other chemotherapeutic agents, such as capecitabine and gemcitabine, has been explored. One approach to overcome these limitations is the modification of traditional Pt(II) drugs to obtain new molecules with an improved pharmacological profile, such as Pt(IV) prodrugs. The design, synthesis, and characterization of two novel Pt(IV) prodrugs based on oxaliplatin bearing the anticancer drugs gemcitabine or capecitabine in the axial positions have been reported. These complexes were able to dissociate into their constituents to promote cell death and induce apoptosis and cell cycle blockade in a representative colorectal cancer cell model. Specifically, the complex bearing gemcitabine resulted in being the most active on the HCT116 colorectal cancer cell line with an IC50 value of 0.49 ± 0.04. A pilot study on the encapsulation of these complexes in biocompatible PLGA-PEG nanoparticles is also included to confirm the retention of the pharmacological properties and cellular drug uptake, opening up to the possible delivery of the studied complexes through their nanoformulation.

pharmacology & pharmacy

What problem does this paper attempt to address?

### What problem does this paper attempt to solve?

This paper aims to address the severe side effects and the tendency to develop resistance associated with traditional platinum-based anticancer drugs (such as cisplatin, oxaliplatin, and carboplatin) during treatment. Specifically, the researchers designed, synthesized, and characterized two novel oxaliplatin(IV) prodrugs, which incorporate gemcitabine or capecitabine as axial ligands. These complexes can dissociate into their components, promote apoptosis, and induce cell cycle arrest in colorectal cancer cell models.

The study also preliminarily explored methods to encapsulate these complexes into biocompatible PLGA-PEG nanoparticles to verify their retention of pharmacological properties and cellular uptake, providing a potential pathway for further development and evaluation of these complexes. Therefore, the main objective of this paper is to improve drug design to enhance efficacy and reduce side effects.